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Sirtuins are genes implicated in cellular and organismal ageing. Consequently, they are speculated to be involved in diseases of ageing
including cancer. Various cancers with widely differing prognosis have been shown to have differing and characteristic expression of
these genes; however, the relationship between sirtuin expression and cancer progression is unclear. In order to correlate cancer
progression and sirtuin expression, we have assessed sirtuin expression as a function of primary cell ageing and compared sirtuin
expression in normal, ‘nonmalignant’ breast biopsies to breast cancer biopsies using real-time polymerase chain reaction (PCR).
Levels of SIRT7 expression were significantly increased in breast cancer (Po0.0001). Increased levels of SIRT3 and SIRT7
transcription were also associated with node-positive breast cancer (Po0.05 and Po0.0001, respectively). This study has
demonstrated differential sirtuin expression between nonmalignant and malignant breast tissue, with consequent diagnostic and
therapeutic implications.
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Breast cancer is the most common cancer to affect women, with
over 40000 new cases being detected and around 13000 women
dying from the disease in Britain each year (CancerStats, 2005).
The prognosis of breast cancer has traditionally been based on
prognostic factors, such as tumour size, nodal status and
histological grade, that have been derived from population-based
studies. To improve the accuracy of predicting prognosis, scoring
systems that combine these factors have been developed, such as
the Nottingham Prognostic Index (NPI) (Galea et al, 1992).
However, these prognostic factors are less accurate predictors of
prognosis in an individual patient, owing to widely differing
disease behaviour that ranges from slow-growing, nonmetastasis-
ing disease with an excellent prognosis, to fast-growing disease
with a propensity for early metastasis and rapid death.
In contrast to the well-defined behaviour of breast cancer in a
population, the molecular aetiology of cancer initiation and
progression is not fully understood. Genes involved in biological
ageing may be informative in this context, as the incidence of
cancer increases as a function of chronological age. Specifically,
genes involved in NAD
þ-dependent protein deacetylation may
have a role to play in cancer pathogenesis (Marks et al, 2001;
Johnstone, 2002; Neumeister et al, 2002). These genes comprise the
sirtuins, orthologues of the yeast silent information regulator 2
(SIR2) family of genes. Sirtuins are a highly conserved set of genes
found in organisms ranging from bacteria to man (Brachmann
et al, 1995; Frye, 2000), involved in a variety of essential cell
processes, including ageing, preventing differentiation, apoptosis
and resistance to metabolic stress (Vaziri et al, 2001; Dryden et al,
2003). We have previously hypothesised that sirtuins, which link
the functions of the mitochondrion, telomere nucleo-protein
complex and ribosome production (the MTR), may be important
contributors to a wide range of ageing related diseases including
cancer (Shiels and Davies, 2003). Consequently, we have under-
taken a study designed to investigate sirtuin expression in breast
cancer. Seven sirtuins (SIRT1–7) have so far been reported in
humans. Of these, SIRT2 and 7 have been associated with particular
cancers with widely varying natural histories, SIRT2 with gliomas
and SIRT7 with thyroid cancer (de Nigris et al, 2002; Frye, 2002;
Hiratsuka et al, 2003). Given the association of sirtuin expression
with clinical behaviour, we investigated sirtuin expression in breast
cancer to determine if changes in the transcriptional expression of
individual sirtuins correlated with malignancy and disease stage.
MATERIALS AND METHODS
Cell culture
Sirtuin expression was initially studied in replicatively ageing
mammary epithelial cell lines. These included a primary mammary
epithelial cell line (HMEC) obtained from Clonetics, UK, an
immortalized nontumorigenic MCF-12A breast cell line from the
Department of Pathology, University of Glasgow and a tumori-
genic MCF-7 breast cancer cell line from the Department of
Radiation Oncology, University of Glasgow. The HMECs were
grown in mammary epithelial cell growth medium (MGEM)
supplemented with bovine pituitary extract (BPE), epidermal
growth factor, insulin, GA-1000 and hydrocortisone. The MCF-12A
cells were grown in a 1:1 mixture of Dulbecco’s modified Eagle’s
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smedium and Ham’s F12 medium, supplemented with 5% foetal calf
serum, 20ngml
 1 epidermal growth factor, 100ngml
 1 cholera
toxin, 0.01mgml
 1 bovine insulin and 500ngml
 1 hydro-
cortisone. The MCF-7 cells were grown in RPMI medium with
10% foetal calf serum.
Biopsies
Archival breast biopsies stored in liquid nitrogen and held by the
Department of Surgery, Western Infirmary, Glasgow, were used for
this study. These biopsies came from patients with potentially
curable, invasive ductal adenocarcinomas who had given permis-
sion for the storage and future analysis of samples of tissue. All
studies were undertaken with the approval of the local NHS ethics
committee.
RNA extraction, DNase treatment and cDNA synthesis
RNA extraction was performed using TRIzol
s (Life Technologies,
UK) on both the mammary epithelial cells and biopsies. Breast
glandular tissue was carefully dissected free from surrounding
fatty tissue. TRIzol
s (1ml) was added per 50mg of tissue. Tissue
was then homogenised using a mechanical tissue homogenizer at
01C. RNA was DNase treated with a commercially available kit
(Ambion, UK) according to the manufacturer’s recommendations.
Then, 2mg of RNA was reverse transcribed into cDNA using the
Superscriptt First Strand Synthesis System (Invitrogen).
Taqman
s polymerase chain reaction (PCR)
Taqman
s PCR was carried out on duplicate cDNA samples using
an ABI Prism 7700 sequence detector in a 25ml reaction. The
mixture consisted of 20ng of cDNA, 300nM of each forward and
reverse primer, 200nM Taqman
s probe, 12.5ml of Taqman
s
Universal PCR Master Mix (Eurogentech, UK) and H2O. Cycle
conditions were 501C for 2min, 951C for 10min followed by 40
cycles of 951C for 15s and 601C for 1min. Sequences of forward
and reverse primers and probes used are shown below (Table 1).
Senescence-associated b-galactosidase assay
The senescence-associated-b-galactosidase (SA-b-Gal) assay
detects the presence of SA-b-Gal, specifically at pH 6, as an
established histochemical marker of cellular senescence (Dimri
et al, 1995). An assessment of the level of SA-b-Gal expression in
all cultures was therefore determined at pH 6 following the method
of Dimri et al (1995), with a pH 4 positive control included in all
instances.
Statistical analysis
The analysis of variance (ANOVA) was used to determine whether
changes in sirtuin expression with replicative ageing were
significant. The comparative DDCT method was employed
to quantify relative gene expression for the Taqman
s studies.
Analysis of individual gene expression between each of biopsy
groups (i.e., normal, and node-positive and negative-breast
biopsies) was performed using ANOVA. Post hoc comparisons
were performed using the independent Student’s t-test. Differences
in gene expression between the biopsy groups were calculated
along with the 95% confidence interval (CI). Results are presented
in figures displaying mean relative gene expression and the
standard error of the mean.
RESULTS
Sirtuin gene expression in primary and immortalised cells was
observed for change over time in culture. Transcriptional
expression for Sirtuins 1, 2, 3 and 7 was undertaken in serially
passaged primary breast cells (HMECs) and in immortalised
nontumorigenic (MCF-12A) and tumorigenic (MCF-7) mammary
epithelial cell lines. This was performed with a view to determining
the transcriptional profile of sirtuins as a function of time spent in
culture and hence biological ageing. SIRT3 and SIRT7 demon-
strated an increase in transcriptional expression with increasing
passage in HMECs (Figure 1). This observation was not repeated
for SIRT1 and SIRT2, nor did any sirtuin analysed showed a change
in transcriptional expression in either of the immortalised cell
lines (Figure 1).
The increase in SIRT3 and SIRT7 expression was concurrent
with an increase in SA-b-Gal expression in the culture with
increasing passage, indicating the presence of increasing amounts
of senescent cells in the population (Figure 2). Neither of the
immortalised cell lines displayed a similar increase in SA-b-Gal
expression. The acquisition of the senescent phenotype by the
HMECs in association with serial passage was confirmed by a
transcriptional analysis of the cellular stress and senescence genes
p16
INK4a and p21
CIP1 (Figure 3). The expression of p16
INK4a increa-
sed with serial passage only in the primary cell line, as did
expression for p21
CIP1, indicating that the transcriptional expres-
sion data for the sirtuins was associated with the generation of a
senescent state in these cells.
Biopsies
The pathological characteristics of the breast biopsies used in this
study were selected to include equal distribution by nodal status
(12 lymph node positive and 12 lymph node negative), and tumour
grade (Table 2). A total of 24 breast cancer samples were chosen
and matched with 21 ‘normal’, nonmalignant breast tissue biopsies
from the breasts of cancer patients. These were then assessed for
sirtuin expression levels.
Relative SIRT7 gene expression was significantly greater in
biopsies from breast cancers compared to ‘normal’, nonmalignant
breast tissue (1.74 (95% CI 1.37–2.10), Po0.001, Figure 4). The
Table 1 The primer and probe sequences used in Taqman
s PCR.
Forward primer (50 –30) Reverse primer (50 –30) Probe (50 FAM–TAMRA 30)
SIRT1 TAGAGCCTCACATGCAAGCTCTA GCCAATCATAAGATGTTGCTGAAC ACTCCAAGGCCACGGATAGGTCCATATACTT
SIRT2 CCTCGCCTGCTCATCAACA TCCTCCGAGGCCCATAATC TGGCCAGTCGGACCCTTT
SIRT3 CATTCGGGCTGACGTGATG AACCACATGCAGCAAGAACCT TGCACCGGCGTTGTGAAGCC
SIRT7 CGTCCGGAACGCCAAATAC GACGCTGCCGTGCTGATT TGGTCGTCTACACAGGC
p21 GCAGACCAGCATGACAGATTTCTA GCGGATTAGGGCTTCCTCTT CACTCCAAACGCCGGCTGATCTTC
p16 CATAGATGCCGCGGAAGT CCCGAGGTTTCTCAGAGCCT CCTCAGACATCCCCGATTGAAAGAACC
18S ACCTGGTTGATCCTGCCAGTAG AGCCATTCGCAGTTTCACTGTAC TCAAAGATTAAGCCATGCATGTCTAAGTACGCAC
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positive compared to node-negative cancers (1.96, (95% CI 1.54–
2.38) vs 1.52 (95% CI 1.13–1.90), Po0.001, Figure 5).
No significant differences in SIRT1, SIRT2 and SIRT3 gene
expression were observed in a simple comparison of biopsies from
breast cancers with ‘normal’ breast tissue (data not shown).
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Figure 1 Sirtuin expression in serially passaged mammary epithelial cell
cultures. The figure shows relative sirtuin gene expression in serially
passaged cells relative to 18s rRNA gene expression. Mean data are plotted
7s.d.
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Figure 2 Senescence associated-b-galactosidase expression in serially
passaged primary and immortalised mammary epithelial cells. Mean SA-b-
Gal expression is shown 7s.d.
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Figure 3 p16 and p21 expression in successively passaged breast cells.
Histograms show the relative gene expression for p16 and p21 relative to
18s rRNA expression in primary cell cultures and immortalized breast cell
lines. Data is plotted as means7s.em.
Table 2 Summary of pathological prognostic factors of breast biopsies
ER status
Lvi
Grade
No Age years (s.e.m.) Nodal status Size mm (s.e.m.) +ve  ve II III NPI (s.e.m.)
Normal 21 61.4 (3.1) N/A N/A N/A N/A N/A N/A
Cancer 24 62.3 (3.1) +ve 30.7 (3.1) 9 3 6 4 8 4.1 (0.2)
 ve 35.7 (3.1) 8 4 5 5 6 6.0 (0.3)
s.e.m.¼standard error of the mean; N/A¼not applicable; ER¼oestrogen receptor; LVi¼lymphovascular invasion; NPI¼Nottingham Prognostic Index.
Sirtuin expression
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also significantly higher in lymph node-positive breast cancer
biopsies when compared to ‘normal’ breast biopsies (1.56, 95% C.I.
1.10–2.01, Po0.05) (Figure 6).
Sirtuin expression was similarly compared by grade, oestrogen
receptor status and the presence of lymphovascular invasion in
both node-positive and node-negative cancers. No significant
differences in sirtuin expression were seen using these factors
(data not shown).
DISCUSSION
We undertook this study to assess the possible association of
changes in the transcriptional expression of individual sirtuin
genes with breast cancer. Firstly, we investigated sirtuin gene
expression in both primary and immortalised cells with a view to
determining how cellular ageing and immortalisation influenced
their transcription profile. Consequently, we observed SIRT3
and SIRT7 transcription to increase in primary cells as they
approach senescence (Figure 1), concurrent with an increase in
p16
INK4a and p21
CIP1 expression (Figure 3) and the accumulation of
SA-b-Gal-containing cells (Figure 2). Secondly, we demonstrated a
significant in vivo association between altered SIRT3 and SIRT7
transcription and malignant breast disease (Figures 4–6).
A link between the transcriptional expression of genes involved
in biological ageing and cancer is pertinent. Individual sirtuins are
respondents to intracellular redox changes and cell stress and
hence biological ageing. In yeast, SIR2 provides a functional link
between the telomere and ribosomal DNA cluster integrity, thus
impacting on ribosome production and enabling the cell to
respond to stress induced redox state changes in the mito-
chondrion (Guarente, 2000). Consequently, damage responses in
the cell can be modulated to match the degree of insult. In man,
individual sirtuins may provide separate functional components of
this process (Shiels and Davies, 2003). This is intriguing, in the
light of the observations that SIRT7 localises to the nucleolus and
SIRT3 localises to the mitochondrion (Onyango et al, 2002;
Michishita et al, 2005). These subcellular locations, along with the
telomere nucleoprotein complex, provide the components of a
functional trinity, we have termed the MTR, that senses, assesses
and signals damage (Shiels and Davies, 2003; Shiels and Jardine,
2003). Our observations that SIRT3 and SIRT7 expression is
increased as primary mammary epithelial cells approach senes-
cence and are also increased in node-positive breast cancer is
in keeping with the MTR hypothesis.
As SIRT7 expression is invariably elevated in thyroid cancer cell
lines and biopsies, increased expression of SIRT7 may represent an
important step in malignant transformation (de Nigris et al, 2002;
Frye, 2002). Indeed, SIRT7 has recently been shown to activate
Pol I encouraging growth and proliferation (Ford et al, 2006). In
this study, we have shown that increased SIRT7 expression is also
observed in breast cancer, and may therefore be postulated, in a
similar manner, to be required for malignant transformation
(Figure 4). Furthermore, SIRT7 expression is also associated with
nodal invasion and therefore locally aggressive disease (Figure 5).
Whether this increased expression contributes to the increased
proliferative potential of mammary cancer cells or reflects a
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Figure 4 SIRT7 expression in normal and breast cancer biopsies.
HIstograms show relative sirtuin gene expression in nonmalignant and
malignant breast biopsies, relative to an 18s rRNA control. Data show
mean sirtuin expression 7s.e.m.
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Figure 5 SIRT7 expression in breast biopsies by nodal status. The
histogram shows relative sirtuin gene expression in nonmalignant and
lymph node-positive and -negative breast cancer biopsies. Data are plotted
as mean sirtuin expression 7s.e.m.
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Figure 6 SIRT3 expression in breast biopsies by nodal status. The
histogram shows relative sirtuin gene expression in nonmalignant and
lymph node-positive and -negative breast cancer biopsies. Data are plotted
as mean sirtuin expression 7s.e.m.
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undetermined. Alternatively, it may reflect a compensatory
mechanism as a consequence of the increased proliferative state.
This is supported by observations on the activity of the yeast
sirtuin orthologue, SIR2. Nucleolar SIR2 activity is a limiting factor
for determining when the cell undergoes senescence (Guarente,
1999). The high proliferative rate in many tumours often results in
them having shortened telomeres as a consequence of rapid cell
turnover outstripping telomerase-mediated telomere repair. This
may, in analogy with the situation in yeast (Guarente, 1999), lead
to an upregulation of sirtuin activity in an attempt to stabilise the
nucleolus. The increased SIRT3 and SIRT7 transcription in
primary mammary epithelial cells, as a consequence of increased
oxidant load with in vitro growth, is supportive of such a scenario.
The association of elevated SIRT7 expression in node-positive
tumours, which have a greater recurrence and poorer survival,
suggests that this gene may prove to be a good marker of disease
progression and tumour behaviour.
There was no overall difference observed in SIRT3 expression
between breast cancer and normal breast tissue. However, on
subdividing the cancer biopsies by nodal status, SIRT3 expression,
like that of SIRT7, was greater in node-positive breast cancer
compared to normal breast tissue (Figure 6). SIRT3 has been
shown to specifically targeted and converted into its active form
within the mitochondria (Dryden et al, 2003; North et al, 2003).
Cumulative mitochondrial damage contributes to a fall in relative
nicotinamide adenine dinucleotide (NAD) levels, and concomitant
fall in SIRT3 activity, and is associated with growth arrest,
senescence and apoptosis (Shiels and Davies, 2003). Analogous to
SIRT1 and SIRT2, SIRT3 may also function to provide a growth and
survival advantage. Indeed, variability of the SIRT3 gene has been
linked to survival in the elderly (Rose et al, 2003). The increased
expression of SIRT3 seen in lymph node-positive tumours may,
therefore, contribute to survival of these more aggressive tumours.
Our data showed that the expression of SIRT1 did not differ
between normal and malignant breast biopsies. This suggests that
transcriptional changes for SIRT1 may not be implicated in breast
cancer pathogenesis. This observation may be pertinent to the p53
status of breast cancers, as p53 is a substrate for SIRT1 (Luo et al,
2001). Unlike the upregulation of telomerase, abnormalities in p53
are seen in only 20–40% of breast cancers, suggesting that
disruption of p53 pathways may be of lesser importance in breast
cancer pathogenesis (Mokbel et al, 2000; Borresen-Dale, 2003).
These data do not, however, negate a role for SIRT1 in breast
cancer pathogenesis, as we looked at overall sirtuin transcriptional
expression levels and not at any putative post-transcriptional
regulation.
The lack of transcriptional change observed for SIRT2 in this
study may be a reflection of a cell cycle dependency in its
expression (Dryden et al, 2003; North et al, 2003). It may be that
more dynamic evaluation of changes in SIRT2 expression at
specific stages of the cell cycle may reveal abnormal patterns of
SIRT2 expression in breast cancer.
The clinical significance of the differences we have observed in
sirtuin expression needs further investigation. Our study has
indicated the potential utility of sirtuins as prognostic markers in
breast cancer. The observation that SIRT7 is increased in breast
cancer tissue compared to normal breast tissue suggests that it
may be related to breast cancer tumorigenesis. The discovery of a
greater expression of SIRT3 and SIRT7, within the prognostically
poorer lymph node-positive breast cancers, suggests that over-
expression of these sirtuins may be related to dissemination.
In summary, the heterogeneity of breast cancer behaviour is
paralleled and may be explained by sirtuin expression. Specifically,
molecular changes in SIRT3 and SIRT7 expression may contribute
to tumour development and disease progression. This study shows
that the study of sirtuins has a potential application in breast
cancer diagnosis and prognosis, as well as in understanding
disease biology.
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